Business Description
Argent Biopharma Ltd
ISIN : AU0000326647
Compare
Compare
Traded in other countries / regions
RGT.AustraliaH5O0.GermanyRGTLF.USA IPO Date
2006-12-21Description
Argent Biopharma Ltd is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialization of nano-engineered therapeutics targeting neurological and immunemediated disorders. Its assets, CannEpil and CimetrA, are for drug-resistant epilepsy and inflammatory conditions, respectively. The company leverages proprietary nano-delivery technologies designed to optimize bioavailability and tissue penetration, including across the blood-brain barrier and pulmonary interfaces. The company operates in a single segment. Geographically, it operates in Malta, Slovenia, UK, and Australia, with the majority of revenue deriving from Slovenia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | -7.29 | |||||
Debt-to-Equity | -1.02 | |||||
Debt-to-EBITDA | -1.28 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -194.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -88 | |||||
3-Year EBITDA Growth Rate | 76.6 | |||||
3-Year EPS without NRI Growth Rate | 75.4 | |||||
3-Year FCF Growth Rate | 77.1 | |||||
3-Year Book Growth Rate | 66.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.54 | |||||
9-Day RSI | 38.11 | |||||
14-Day RSI | 39.44 | |||||
3-1 Month Momentum % | 8.11 | |||||
6-1 Month Momentum % | -6.98 | |||||
12-1 Month Momentum % | -65.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.05 | |||||
Quick Ratio | 0.05 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 419.48 | |||||
Days Sales Outstanding | 489.69 | |||||
Days Payable | 2493.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -221.3 | |||||
Shareholder Yield % | -17.93 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -24.85 | |||||
Operating Margin % | -5140.99 | |||||
Net Margin % | -4788.82 | |||||
EBITDA Margin % | -4665.84 | |||||
FCF Margin % | -2501.24 | |||||
OCF Margin % | -2500 | |||||
ROA % | -400.66 | |||||
ROIC % | -101.92 | |||||
3-Year ROIIC % | -79.72 | |||||
ROC (Joel Greenblatt) % | -3494.84 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 15.5 | |||||
EV-to-EBIT | -1.7 | |||||
EV-to-EBITDA | -1.74 | |||||
EV-to-Forward-EBITDA | 404.98 | |||||
EV-to-Revenue | 81.13 | |||||
EV-to-Forward-Revenue | 1.93 | |||||
EV-to-FCF | -3.3 | |||||
Price-to-GF-Value | 3.1 | |||||
Earnings Yield (Greenblatt) % | -58.83 | |||||
FCF Yield % | -111.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Argent Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.161 | ||
| EPS (TTM) (A$) | -0.089 | ||
| Beta | 0.7612 | ||
| 3-Year Sharpe Ratio | -1.53 | ||
| 3-Year Sortino Ratio | -1.71 | ||
| Volatility % | 49.42 | ||
| 14-Day RSI | 39.44 | ||
| 14-Day ATR (A$) | 0.003019 | ||
| 20-Day SMA (A$) | 0.03375 | ||
| 12-1 Month Momentum % | -65.22 | ||
| 52-Week Range (A$) | 0.03 - 0.13 | ||
| Shares Outstanding (Mil) | 116.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Argent Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Argent Biopharma Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-02-27 | 0.06 (+0.00%) | ||
| General meeting for 2025 | 2025-11-28 16:00 | 0.08 (+5.26%) | ||
| Annual report for 2025 | 2025-09-30 | 0.10 (-2.04%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 0.14 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-02-28 | 0.14 (+0.00%) | ||
| General meeting for 2024 | 2024-11-28 16:00 | 0.25 (-1.96%) | ||
| Annual report for 2024 | 2024-09-30 | 0.36 (+1.43%) | ||
| 0.001:1 Stock Split | 2023-10-30 | 1.00 (+0.00%) | ||
| 0.1:1 Stock Split | 2012-08-21 | 187.50 (+0.00%) |
Show
Entries
Argent Biopharma Ltd Frequently Asked Questions
What is Argent Biopharma Ltd(ASX:RGT)'s stock price today?
The current price of ASX:RGT is A$0.03. The 52 week high of ASX:RGT is A$0.13 and 52 week low is A$0.03.
When is next earnings date of Argent Biopharma Ltd(ASX:RGT)?
The next earnings date of Argent Biopharma Ltd(ASX:RGT) is 2027-02-27 Est..
Does Argent Biopharma Ltd(ASX:RGT) pay dividends? If so, how much?
Argent Biopharma Ltd(ASX:RGT) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers